Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma

Citation
L. Vakeva et al., Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma, J INVES DER, 115(1), 2000, pp. 62-65
Citations number
34
Categorie Soggetti
Dermatology,"da verificare
Journal title
JOURNAL OF INVESTIGATIVE DERMATOLOGY
ISSN journal
0022202X → ACNP
Volume
115
Issue
1
Year of publication
2000
Pages
62 - 65
Database
ISI
SICI code
0022-202X(200007)115:1<62:IROSCI>2.0.ZU;2-3
Abstract
As putative etiologic factors of primary cutaneous T cell lymphomas may hav e a general cancerogenic effect, we wanted to assess the risk of secondary malignancies in 319 patients diagnosed with histopathologically verified cu taneous T cell lymphomas and reported to the Finnish Cancer Registry during the years 1953-95. Standardized incidence ratios were defined as the ratio of observed to expected numbers of cases. To obtain the expected numbers o f cancer, age-, sex-, and period-specific Finnish incidence rates were appl ied to the appropriate person-years under observation. Ninety-five percent confidence intervals were calculated assuming a Poisson distribution. For t he whole period, we detected 36 secondary cancers whereas 26 were expected (standardized incidence ratios 1.4, 95% confidence intervals 1.0-1.9). The overall risk of lung cancer was significantly increased (standardized incid ence ratio was 2.7, 95% confidence intervals were 1.4-4.8); and in particul ar small-cell lung cancer showed high standardized incidence ratios (standa rdized incidence ratio was 8.5, 95% confidence intervals were 2.8-20). Also , the risk of lymphomas was elevated (standardized incidence ratios for Hod gkin and non-Hodgkin lymphomas combined were 7.0, 95% confidence intervals were 1.9-18). The incidence of other cancers was similar to the national ra tios. An increased risk of secondary cancers and in particular small-cell c ancer of the lung and lymphomas among patients with primary cutaneous T cel l lymphoma is demonstrated. In clinical practice, lung cancer and lymphomas must be kept in mind when following up patients with cutaneous T cell lymp homas.